Accredited CME: Still Viable for Pharma?

By July 3, 2015The MEDUCOM Post

The development process for accredited CME is becoming increasingly more restrictive – the College of Family Physicians of Canada (CFPC) policy is NO industry involvement in the content development process, and the Royal College of Physicians and Surgeons of Canada (RCPSC) is in the process of revising their Standards for Commercial Support). This is causing many in the industry to ask if they should continue to invest in accredited CME.

The answer is yes, it remains a good investment, provided achievable communications objectives are clearly defined and a plan is developed to ensure the resulting CME program is on strategy. For example, within the CFPC framework, pharma companies (and their agencies) can be involved in selecting the Planning Committee and providing administrative support. With the right approach, this allows enough latitude to create a CME program that meets the needs of all stakeholders.

Pages: 1 2